

Integrin α1/CD49a Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 200	Source/Isotype: Rabbit	UniProt ID: #P56199	Entrez-Gene Id: 3672
Product Usage Information		Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. <i>Do not aliquot the antibody.</i>				
Specificity/Sensitivity		Integrin α 1/CD49a Antibody recognizes endogenous levels of total integrin α 1/CD49a protein.				
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu794 of human integrin α 1/CD49a protein. Antibodies are purified by protein A and peptide affinity chromatography.				
Background		Integrins are α/β heterodimeric cell surface receptors that play a pivotal role in cell adhesion and migration, as well as in growth and survival (1,2). The integrin family contains at least 18 α and 8 β subunits that form 24 known integrins with distinct tissue distribution and overlapping ligand specificities (3). Integrins not only transmit signals to cells in response to the extracellular environment (outside-in signaling), but also sense intracellular cues to alter their interaction with the extracellular environment (inside-out signaling) (1,2). Integrin α 1 (CD49a, VLA-1, ITGA1) pairs with integrin β 1 to form an α 1 β 1 dimer on the cell surface. This integrin dimer plays important roles in colorectal cancer and pancreatic cancer cell proliferation, migration, and metastasis (4-6). The cytoplasmic tail of integrin α 1 activates ERK and FAK/Src signaling to promote these biological processes (7,8). In immune systems, integrin α 1 expression defines a tissue-resident cytotoxic T cell population contributing to both cancer immunity and vitiligo, an autoimmune disease (9,10).				
Background References		 Liu, S. et al. (2000) J Cell Sci 113 (Pt 20), 3563-71. Hood, J.D. and Cheresh, D.A. (2002) Nat Rev Cancer 2, 91-100. Hogervorst, F. et al. (1993) J Cell Biol 121, 179-91. Gharibi, A. et al. (2017) Sci Rep 7, 10060. Boudjadi, S. et al. (2017) Cancers (Basel) 9, pii: E96. doi: 10.3390/cancers9080096. Shang, L. et al. (2017) Oncotarget 8, 76816-31. Abair, T.D. et al. (2008) Blood 112, 3242-54. Van Slambrouck, S. et al. (2007) Int J Oncol 31, 1501-8. Cheuk, S. et al. (2017) Immunity 46, 287-300. Molodtsov, A. and Turk, M.J. (2018) Front Immunol 9, 2810. 				
Species Reactivi	ty	Species reactivity is d	etermined by testir	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X				

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key W: Western Blotting

Cross-Reactivity Key H: Human M: Mouse R: Rat

Trademarks and Patents Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.